Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 4/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.40 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962451 | 0.92 | NQO1 (0.52) | NQO1ADORA3CYP2C9HSD17B10CYP3A4 | |
| SCHEMBL7219958 | 0.92 | NQO1 (0.42) | NQO1ADORA3CYP2C9HSD17B10CYP3A4 | |
| SCHEMBL6918020 | 0.91 | NQO1 (0.50) | NQO1ADORA3CYP2C9HSD17B10CYP3A4 | |
| SCHEMBL5113244 | 0.88 | NQO1 (0.53) | NQO1ADORA3CYP2C9HSD17B10CYP3A4 | |
| SCHEMBL4960715 | 0.87 | ADORA3 (0.51) | NQO1ADORA3CYP2C9MEN1KMT2A | |
| SCHEMBL4957327 | 0.84 | ADORA3 (0.57) | NQO1ADORA3CYP2C9HSD17B10CYP3A4 | |
| SCHEMBL4961559 | 0.83 | NQO1 (0.53) | NQO1ADORA3CYP2C9 | |
| SCHEMBL5107208 | 0.82 | ADORA3 (0.53) | NQO1ADORA3CYP2C9KDM4EALDH1A1 | |
| SCHEMBL4958904 | 0.80 | MEN1 (0.57) | NQO1CYP2C9MEN1KMT2A | |
| SCHEMBL4962535 | 0.80 | NQO1 (0.58) | NQO1CYP2C9HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | NQO1 249/4885ADORA3 2300/4885CYP2C9 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.